WO 2017/091533 Al 1 June 20 17 (0 1.06.20 17) W P O P C T

Total Page:16

File Type:pdf, Size:1020Kb

WO 2017/091533 Al 1 June 20 17 (0 1.06.20 17) W P O P C T (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/091533 Al 1 June 20 17 (0 1.06.20 17) W P O P C T (51) International Patent Classification: Plaza 721/2340, 974 Centre Road, PO Box 291 5 Wilming A23L 33/10 (201 6.01) CI2N 9/10 (2006.01) ton, Delaware 19805 (US). A61K 31/716 (2006.01) C08L 5/00 (2006.01) (81) Designated States (unless otherwise indicated, for every C 37/00 (2006.01) C08L 5/02 (2006.01) kind of national protection available): AE, AG, AL, AM, C12P 19/04 (2006.01) A23L 33/135 (2016.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, CUP 19/08 (2006.01) A23L 33/21 (201 6.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, CUP 19/16 (2006.01) A61K 8/73 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, CUP 19/18 (2006.01) HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (21) International Application Number: KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, PCT/US2016/063233 MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (22) International Filing Date: SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, 22 November 2016 (22.1 1.2016) TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, (25) Filing Language: English ZW. (26) Publication Language: English ( ) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (30) Priority Data: GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, PCT/CN2015/095687 TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, 26 November 2015 (26. 11.2015) CN TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, PCT/CN2016/085547 13 June 2016 (13.06.2016) CN DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, (71) Applicant: E. I. DU PONT DE NEMOURS AND COM¬ LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, PANY [US/US]; Chestnut Run Plaza, 974 Centre Road, P. SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, O. Box 2915, Wilmington, Delaware 19805 (US). GW, KM, ML, MR, NE, SN, TD, TG). (72) Inventors: CHENG, Qiong; 4 Collins Drive, Wilmington, Published: Delaware 19803 (US). DICOSIMO, Robert; 1607 Mas — with international search report (Art. 21(3)) ters Way, Chadds Ford, Pennsylvania 193 17-9720 (US). — before the expiration of the time limit for amending the PRASAD, Jahnavi Chandra; 2124 Haven Road, Apt F, claims and to be republished in the event of receipt of Wilmington, Delaware 19809 (US). ZHANG, Zhenghong; amendments (Rule 48.2(h)) Room 2702, Building 13, Lane 655, Chengyin Road, Baoshan District, Shanghai 200444 (CN). — with sequence listing part of description (Rule 5.2(a)) (74) Agent: CHESIRE, Dennis; E. I. du Pont de Nemours and Company, Legal Patent Records Center, Chestnut Run © - © (54) Title: POLYPEPTIDES CAPABLE OF PRODUCING GLUCANS HAVING ALPHA- 1,2 BRANCHES AND USE OF THE SAME (57) Abstract: Disclosed herein are proteins capable of forming glucans having alpha- 1,2 linkages/branches, reactions and methods for producing such glucan, compositions comprising such glucan, and various applications thereof. POLYPEPTIDES CAPABLE OF PRODUCING GLUCANS HAVING ALPHA- 1,2 BRANCHES AND USE OF THE SAME This application claims the benefit of International Application Nos. PCT/CN20 15/095687 (filed November 26, 2015) and PCT/CN2016/085547 (filed June 13, 2016), both of which are incorporated herein by reference in their entireties. FIELD OF INVENTION The disclosure relates to, for example, proteins that are capable of forming glucan having alpha- 1,2 linkages, reactions and methods for producing such glucan, compositions comprising this glucan, and various applications of using this glucan. REFERENCE TO SEQUENCE LISTING SUBMITTED ELECTRONICALLY The official copy of the sequence listing is submitted electronically via EFS-Web as an ASCII formatted sequence listing with a file named 20161 122_CL6550WOPCT3_SequenceListingExtraLinesRemoved.txt created on November 21, 2016 and having a size of 413 kilobytes and is filed concurrently with the specification. The sequence listing contained in this ASCII-formatted document is part of the specification and is herein incorporated by reference in its entirety. BACKGROUND The enzymatic addition of alpha- 1,2 branching to dextrans has been reported. A glucosyltransferase (DsrE) from Leuconostoc mesenteroides NRRL B-1299 has a second catalytic domain ("CD2") capable of adding alpha-1,2 branching to dextrans (U.S. Patent Nos. 7439049 and 5141858; U.S. Patent Appl. Publ. No. 2009-0123448; Bozonnet et al., J. Bacteriol. 184:5753-5761, 2002). U.S. Patent Appl. Pub. No. 2010-0284972 describes methods and compositions for improving the health of a subject by administering compositions comprising alpha-1,2-branched alpha-1,6 dextrans. Sarbini et al. (Appl. Environ. Microbiol. 77:5307-5315, 2011) describes in vitro fermentation of dextran and alpha-1,2-branched dextrans by human fecal microbiota. Brison et al. (J. Biol. Chem. 287:7915-7924, 2012) describes a truncated form of the DsrE glucosyltransferase from Leuconostoc mesenteroides NRRL B-1299 (a glucan binding domain [GBD] coupled to the second catalytic domain, CD2 [i.e., GBD-CD2]) that is capable of adding alpha-1,2 branching to dextrans. Despite these reports, there remains a need to identify further enzymes that are capable of producing glucans having alpha-1,2 linkages. SUMMARY In one aspect, the present disclosure regards a reaction composition comprising at east water, sucrose, an aipha-glucan substrate, and a polypeptide that is capable of forming at least one a!pha-1,2 branch frora the alpha-glucan substrate, wherein the polypeptide comprises an ammo acid sequence tha is at least 90% identical to: (i) the mature form of a sequence selected from the group consisting of SEQ ID NOs:4, , 2, 3, 5, , 7, 8, 9, 10, 11, 12, and 13; (ii) SEQ ID NO: or a sub-sequence within any one of SEQ ID NOs:4, 2, 3, 5, 6, 7, 8, 9, 10, , 12, or 13 that aligns with SEQ ID NO:27; and/or (iii) a sequence selected from the group consisting of SEQ ID N()s:4, , 2, 3, 5, 6, 7, 8, 9, 10, 11, 12, and 13. The present disclosure also concerns a method of producing a glucan composition that comprises alpha-1,2 linkages, the method comprising: (a) providing at least the following reaction components: water, sucrose, an alpha- glucan substrate, and a polypeptide that is capable of forming at least one alpha-1,2 branch from the alpha-glucan substrate, wherein the polypeptide comprises an amino acid sequence that is at least 90% identical to: (i) the mature form of a sequence selected frora the group consisting of SEQ ID N()s:4, , 2, 3, 5, 6, 7, 8, 9, 0, , 2, and 3; ( i) SEQ ID NO:27 or a sub-sequence within any one of SEQ ID NOs:4, 2, 3, 5, 6, 7, 8, 9, 10, , 12, or 13 that aligns with SEQ ID NO:27; and/or (in) a sequence selected frora the group consisting of SEQ ID NOs:4, 1, 2, 3, 5, 6, 7, 8, 9, 10, , 12, and 13; (b) combining the reaction components under suitable conditions whereby the polypeptide catalyzes the synthesis of at least one alpha-1,2 branch frora the alpha- glucan substrate, thereby forming a glucan composition comprising alpha-1,2 linkages; and (c) optionally isolating the glucan composition comprising alpha-1,2 linkages. The present disclosure also concerns a composition that comprises a glucan composition comprising one or more alpha-1,2 linkages produced by a method or reaction as described herein, preferably wherein the composition is in the form of a food product, pharmaceutical product, personal care product, household care product, or industrial product, optionally wherein the composition comprises about 0.01 to 99 wt% (dry solids basis) of the glucan composition. The present disclosure also concerns a method comprising enterally administering a substance to a mammal, wherein the substance comprises a glucan composition comprising alpha- 1,2 linkages, wherein the administering results in less or slower blood glucose elevation in the mammal as compared to a mamma! that is enteraily administered a substance that lacks the glucan composition but instead contains a same amount of a readily digestible glucose-containing carbohydrate, wherein the glucan composition is produced by a method or reaction as described herein, optionally wherein the mammal is a human, and optionally wherein the readily digestible glucose-containing carbohydrate is sucrose, free glucose, or starch. The present disclosure also concerns a method of producing a food or beverage, the method comprising incorporating a glucan composition comprising alpha- 1,2 linkages into the food or beverage, wherein the glycemic index of the resulting food or beverage is not increased, or only marginally increased, compared to a food or beverage that lacks the glucan composition, and wherein the glucan composition is produced by a method or reaction as described herein. BRIEF DESCRIPTION OF THE BIOLOGICAL SEQUENCES The identification (gi) and accession numbers provided below are from GENEBANK (available at National Center for Biotechnology Information [NCBI] website). SEQ ID NO:l is the amino acid sequence of full length GTFJ18 (old gi: 356644413, new gi: 504090610, Acc.
Recommended publications
  • Sodium Citrate As Processing Aid (Anticoagulant) for Spray Dried Blood Products
    From: Protena Nicaragua Proteína Naturales, S.A. Km 27, Panamericana Norte Nicaragua To: Program Manager, USDA/AMS/TM/NOP, Room 4008-So., Ag Stop 0268, 1400 Independence Ave., SW., Washington, DC 20250 Phone: (202) 720–3252 Fax: (202) 205–7808. [email protected] (electronic submission) Subject: Petition: Sodium Citrate as Processing Aid (Anticoagulant) for Spray Dried Blood Products In this petition, we address each of the Items listed in the new NOP 3011: National List Petition Guidelines (effective March 11, 2016) Most all of the information contained in this petition has already been made available to USDA-NOP in the Technical Evaluation Report for Citric acid and Salts (Handling/Processing), compiled by OMRI for the USDA National Organic Program, Feb 17, 2015 (See attachment # 1 – Sodium Citrate TR2015) https://www.ams.usda.gov/sites/default/files/media/Citric%20Acid%20TR%202015.pdf. Direct quotes from this report are “italics”. Since citric acid is a necessary precursor for sodium citrate, citric acid is also an essential part of this evaluation. Sodium citrate is produced when citric acid is mixed with sodium hydroxide or sodium bicarbonate. Item A.1 — This is a petition to include Sodium Citrate in the List of Synthetic substances allowed for use in organic crop production (§ 205.601). If approved, sodium citrate would be allowed as synthetic organic ingredient (anticoagulant) for processing bovine blood after collection at slaughter, so the blood will maintain a liquid state while being processed into organic crop fertilizer (spray dried blood meal and spray dried hemoglobin). Item A.2 — The OFPA Category (7 U.S.C.
    [Show full text]
  • Fluoride Gels Help Prevent and Control Dental Caries | ACFF
    Fluoride Gels Full Summary Description: Fluoride-containing gels have been used as topical applications for over 50 years in order to help prevent or control dental caries. The gels were historically intended as a professional measure but nowadays are also used for self-application at home. In both cases, a prescription from a dentist is required. There are three principal gel formulations available , i) 2% sodium fluoride with neutral or basic pH, ii) 1.23% acidulated phosphate fluoride (APF) with pH around 3.5, and iii) 1.25% amine fluoride gel (0.25% of the amine fluorides olaflur and dectaflur, and the rest in the form of 1% sodium fluoride). The gels are flavored and colored but contain no abrasive cleaning agents or preservatives. The clinical characteristics high fluoride concentration and a long contact time with the teeth allow the dental professional to place the fluoride gel allowing for long interval between fluoride gel applications. Use and application: The treatment is preceded by professional tooth cleaning, rinsing and air drying in all patients with sub-optimal oral hygiene. The gels are applied with the aid of plastic or disposable Styrofoam trays of adequate size for the patient. The tray should cover the entire dentition and reach beyond the neck of the teeth and contact the alveolar mucosa. In rare cases, individual custom fit trays can be considered. A ribbon of gel is placed in the tray which is seated over the entire dental arch. It is recommended that the trays are kept in place for 4 minutes and the patient is advised not to eat, drink or rinse for 30 minutes following the application.
    [Show full text]
  • Precautions Interactions Pharmacokinetics
    Sodium Silicofluoride 2091 7. McDonagh MS, et al. Systematic review of water fluoridation. BMJ 2000; r r Crest; Sensodyne iso-active; Soluvite; Tri-A-Vite F; Tri-Vi-Flor; 321: 855-9. P.. �P.?. c:Jii?,n,�............................. ............................................. Tri-Vi-Floro; Trivitamin Fluoride Drops; Vi-Daylin/F; Venez. : 8. Rock WP, Sabieha AM The relationship between reported toothpaste . (details are given in Volume B) Sensodyne. usage in infancy and fluorosis of permanent incisors. Br Dent J 1997; 183: ProprietaryPreparations 165-70. Single-ingredientPrepara6ons, Arg. : Aquafresh Ultimate White; 9. Steiner M, et al. Effect of 1000 ppm relative to 250 ppm fluoride Elgydium Junior; Elgydium ProtecTion Caries; Fluordent; PharmacopoeialPrepara6ons toothpaste: a meta-analysis. Am J Dent 2004; 17: 85-8. BP 2014: Sodium Fluoride Mouthwash; Sodium Fluoride Oral Fluorogel; Fluoroplat; Naf Buches; Opalescence; Austral.: Flur­ Drops; Sodium Fluoride Oral Solution; Sodium Fluoride Tablets; etst; NeutraFluor; Austria: Duraphat; Fluodontt; Sensodyne 36: Gum disease. In the Davangere district of India, the fluo­ USP Minerals Capsules; Minerals Tablets; Oil- and Water­ Proschmelz; Zymafluor; Belg.: Fluodontyl; Fluor; Z-Fluor; soluble Vitamins with Minerals Capsules; Oil- and Water-soluble ride concentration in the drinking water ranges from 1.5 Braz.: Fluotrat; Canad. : Fluocalt; Fluor-A-Day; Nafrinset; Oro­ Vitamins with Minerals Oral Solution; Oil- and Water-soluble to 3 ppm; there is virtually no dental care. In a study of NaFt;
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • Effect of 10% Fluoride on the Remineralization of Dentin in Situ
    www.scielo.br/jaos http://dx.doi.org/10.1590/1678-775720150239 dentin in situ 0R]KJDQ %,=+$1*1, Sabine KALETA-KRAGT1, Preeti SINGH-HÜSGEN2, Markus Jörg ALTENBURGER3, Stefan ZIMMER1 1- University Witten/Herdecke, Department of Operative and Preventive Dentistry, Witten, Germany. 2- Heinrich-Hein University Duesseldorf, Department of Operative and Preventive Dentistry and Periodontics, Duesseldorf, Germany. 3- Universitätsklinikum Freiburg, Department of Operative Dentistry and Periodontology, Freiburg, Germany. Corresponding address: Mozhgan Bizhang - University Witten/Herdecke - Department of Operative and Preventive Dentistry - Alfred-Herrhausen-Str. 50 - 58448 Witten - Germany - Phone: +49 2302 926 653 - Fax +49 2302 926 661 - e-mail: [email protected] 6XEPLWWHG0D\0RGL¿FDWLRQ$XJXVW$FFHSWHG6HSWHPEHU ABSTRACT bjective: The purpose of this randomized, cross-over, in situ study was to determine Othe remineralization of demineralized dentin specimens after the application of a 10% uoride - or a 1% chlorheidine1% thymol thymol varnish aterial and ethods: Twelve individuals without current caries activity wore removable appliances in the lower jaw for a period of four weeks. Each appliance contained four human demineralized dentin specimens ed on the buccal aspects. The dentin specimens were obtained from the cervical regions of extracted human third molars. After demineralization, half the surface of each specimen was covered with a nail varnish to serve as the reference surface. The dentin specimens were randomly assigned to one of the three groups: F-, CHX–thymol, and control no treatment. efore the rst treatment period and between the others, there were washout periods of one week. After each treatment phase, the changes in mineral content (vol% μm) and the lesion depths (μm) of the dentin slabs were determined by transverse microradiography (TMR).
    [Show full text]
  • An in Vitro and in Vivo Study of Fluoride Uptake by Dentine Following Application of Various Topical Fluoride Regimens
    AN IN VITRO AND IN VIVO STUDY OF FLUORIDE UPTAKE BY DENTINE FOLLOWING APPLICATION OF VARIOUS TOPICAL FLUORIDE REGIMENS Nicola Jane Woodley A thesis submitted for the degree of Doctor of Philosophy in the Faculty of Dentistry University of London Departments of Biomaterials and Prosthetic Dentistry Eastman Dental Institute for Oral Health Care Sciences -1999- ProQuest Number: U641832 All rights reserved INFORMATION TO ALL USERS The quality of this reproduction is dependent upon the quality of the copy submitted. In the unlikely event that the author did not send a complete manuscript and there are missing pages, these will be noted. Also, if material had to be removed, a note will indicate the deletion. uest. ProQuest U641832 Published by ProQuest LLC(2015). Copyright of the Dissertation is held by the Author. All rights reserved. This work is protected against unauthorized copying under Title 17, United States Code. Microform Edition © ProQuest LLC. ProQuest LLC 789 East Eisenhower Parkway P.O. Box 1346 Ann Arbor, Ml 48106-1346 ABSTRACT Restoration of severely worn dentitions frequently involves the use of overlay dentures. Such treatment can lead to the rapid development of caries. Topical fluoride regimens, including sodium fluoride, amine fluoride or stannous fluoride, have been used to reduce this risk. Sodium fluoride is regarded as effective but the other two compounds to be evaluated have benefits such as deposition of acid insoluble salts on the tooth surface. However stannous fluoride can be unstable and it has been suggested that amine fluoride/stannous fluoride combinations may be more effective. This study investigated the three fluoride containing compounds both alone and in combination to measure the effects on the fluoride content of dentine both in vitro and in vivo.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Oral Care Compositions Containing Free-B-Ring Flavonoids and Flavans
    (19) & (11) EP 2 308 565 A2 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 13.04.2011 Bulletin 2011/15 A61Q 11/02 (2006.01) A61Q 11/00 (2006.01) A61K 8/19 (2006.01) A61K 8/21 (2006.01) (2006.01) (2006.01) (21) Application number: 11151708.2 A61K 8/25 A61K 8/27 A61K 8/29 (2006.01) A61K 8/49 (2006.01) (2006.01) (2006.01) (22) Date of filing: 21.12.2005 A61K 8/81 A61P 29/00 (84) Designated Contracting States: • Viscio, David AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Monmouth Junction, NJ 08852 (US) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI • Gaffar, Abdul SK TR Princeton, NJ 08540 (US) • Mello, Sarita V. (30) Priority: 22.12.2004 US 639331 P Somerset, NJ 08873 (US) 12.12.2005 US 301098 • Arvanitidou, Evangelia S. Princeton, NJ 08540 (US) (62) Document number(s) of the earlier application(s) in • Prencipe, Michael accordance with Art. 76 EPC: West Windsor, NJ 08550 (US) 05855133.4 / 1 827 608 (74) Representative: Jenkins, Peter David (71) Applicant: Colgate-Palmolive Company Page White & Farrer New York NY 10022-7499 (US) Bedford House John Street (72) Inventors: London WC1N 2BF (GB) • Xu, Guofeng Princeton, NJ 08542 (US) Remarks: • Boyd, Thomas, J. This application was filed on 21-01-2011 as a Metuchen, NJ 08840 (US) divisional application to the application mentioned • Hao, Zhigang under INID code 62. North Brunswick, NJ 08902 (US) (54) ORAL CARE COMPOSITIONS CONTAINING FREE-B-RING FLAVONOIDS AND FLAVANS (57) Oral care compositions containing: a free-B-ring flavonoid and a flavan; as well as at least one bioavailability- enhancing agent are provided.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,158,152 B2 Palepu (45) Date of Patent: Apr
    US008158152B2 (12) United States Patent (10) Patent No.: US 8,158,152 B2 Palepu (45) Date of Patent: Apr. 17, 2012 (54) LYOPHILIZATION PROCESS AND 6,884,422 B1 4/2005 Liu et al. PRODUCTS OBTANED THEREBY 6,900, 184 B2 5/2005 Cohen et al. 2002fOO 10357 A1 1/2002 Stogniew etal. 2002/009 1270 A1 7, 2002 Wu et al. (75) Inventor: Nageswara R. Palepu. Mill Creek, WA 2002/0143038 A1 10/2002 Bandyopadhyay et al. (US) 2002fO155097 A1 10, 2002 Te 2003, OO68416 A1 4/2003 Burgess et al. 2003/0077321 A1 4/2003 Kiel et al. (73) Assignee: SciDose LLC, Amherst, MA (US) 2003, OO82236 A1 5/2003 Mathiowitz et al. 2003/0096378 A1 5/2003 Qiu et al. (*) Notice: Subject to any disclaimer, the term of this 2003/OO96797 A1 5/2003 Stogniew et al. patent is extended or adjusted under 35 2003.01.1331.6 A1 6/2003 Kaisheva et al. U.S.C. 154(b) by 1560 days. 2003. O191157 A1 10, 2003 Doen 2003/0202978 A1 10, 2003 Maa et al. 2003/0211042 A1 11/2003 Evans (21) Appl. No.: 11/282,507 2003/0229027 A1 12/2003 Eissens et al. 2004.0005351 A1 1/2004 Kwon (22) Filed: Nov. 18, 2005 2004/0042971 A1 3/2004 Truong-Le et al. 2004/0042972 A1 3/2004 Truong-Le et al. (65) Prior Publication Data 2004.0043042 A1 3/2004 Johnson et al. 2004/OO57927 A1 3/2004 Warne et al. US 2007/O116729 A1 May 24, 2007 2004, OO63792 A1 4/2004 Khera et al.
    [Show full text]
  • Drug Consumption at Wholesale Prices in 2017 - 2020
    Page 1 Drug consumption at wholesale prices in 2017 - 2020 2020 2019 2018 2017 Wholesale Hospit. Wholesale Hospit. Wholesale Hospit. Wholesale Hospit. ATC code Subgroup or chemical substance price/1000 € % price/1000 € % price/1000 € % price/1000 € % A ALIMENTARY TRACT AND METABOLISM 321 590 7 309 580 7 300 278 7 295 060 8 A01 STOMATOLOGICAL PREPARATIONS 2 090 9 1 937 7 1 910 7 2 128 8 A01A STOMATOLOGICAL PREPARATIONS 2 090 9 1 937 7 1 910 7 2 128 8 A01AA Caries prophylactic agents 663 8 611 11 619 12 1 042 11 A01AA01 sodium fluoride 610 8 557 12 498 15 787 14 A01AA03 olaflur 53 1 54 1 50 1 48 1 A01AA51 sodium fluoride, combinations - - - - 71 1 206 1 A01AB Antiinfectives for local oral treatment 1 266 10 1 101 6 1 052 6 944 6 A01AB03 chlorhexidine 930 6 885 7 825 7 706 7 A01AB11 various 335 21 216 0 227 0 238 0 A01AB22 doxycycline - - 0 100 0 100 - - A01AC Corticosteroids for local oral treatment 113 1 153 1 135 1 143 1 A01AC01 triamcinolone 113 1 153 1 135 1 143 1 A01AD Other agents for local oral treatment 49 0 72 0 104 0 - - A01AD02 benzydamine 49 0 72 0 104 0 - - A02 DRUGS FOR ACID RELATED DISORDERS 30 885 4 32 677 4 35 102 5 37 644 7 A02A ANTACIDS 3 681 1 3 565 1 3 357 1 3 385 1 A02AA Magnesium compounds 141 22 151 22 172 22 155 19 A02AA04 magnesium hydroxide 141 22 151 22 172 22 155 19 A02AD Combinations and complexes of aluminium, 3 539 0 3 414 0 3 185 0 3 231 0 calcium and magnesium compounds A02AD01 ordinary salt combinations 3 539 0 3 414 0 3 185 0 3 231 0 A02B DRUGS FOR PEPTIC ULCER AND 27 205 5 29 112 4 31 746 5 34 258 8
    [Show full text]
  • On the Safety Assessment of Citric Acid, Inorganic Citrate Salts, and Alkyl Citrate Esters As Used in Cosmetics
    Final Report On the Safety Assessment of Citric Acid, Inorganic Citrate Salts, and Alkyl Citrate Esters as Used in Cosmetics March 27, 2012 The 2012 Cosmetic Ingredient Review Expert Panel members are: Chair, Wilma F. Bergfeld, M.D., F.A.C.P.; Donald V. Belsito, M.D.; Ronald A. Hill, Ph.D.; Curtis D. Klaassen, Ph.D.; Daniel Liebler, Ph.D.; James G. Marks, Jr., M.D., Ronald C. Shank, Ph.D.; Thomas J. Slaga, Ph.D.; and Paul W. Snyder, D.V.M., Ph.D. The CIR Director is F. Alan Andersen, Ph.D. This report was prepared by Monice M. Fiume, Senior Scientific Analyst/Writer and Bart A. Heldreth, Ph.D., Chemist. © Cosmetic Ingredient Review 1101 17th Street, NW, Suite 412 ♢ Washington, DC 20036-4702 ♢ ph 202.331.0651 ♢ fax 202.331.0088 ♢ [email protected] ABSTRACT: The CIR Expert Panel assessed the safety of citric acid, 12 inorganic citrate salts, and 20 alkyl citrate esters as used in cosmetics, concluding that these ingredients are safe in the present practices of use and concentration. Citric acid is reported to function as a pH adjuster, chelating agent, or fragrance ingredient. Some of the salts are also reported to function as chelating agents, and a number of the citrates are reported to function as skin conditioning agents. The Panel reviewed available animal and clinical data; because, citric acid, calcium citrate, ferric citrate, manganese citrate, potassium citrate, sodium citrate, diammonium citrate, isopropyl citrate, stearyl citrate, and triethyl citrate are GRAS direct food additives, dermal toxicity was the focus for these ingredients in this assessment.
    [Show full text]
  • Elmex Medical Cariësprotectiegel Qsodium Fluoride, Amine Fluoride; Olaflur and Dectaflur)
    Case: 306194 RVG: 06269 Elmex Medical Cariësprotectiegel QSodium fluoride, Amine Fluoride; Olaflur and dectaflur) Abbreviated PSUR ASSESSMENT REPORT 13 September 2013 Pharmaceutical form(s) Dental gel 12,5 mg/g MAH(s) Gaba B.V. IBD/EU BD 17 June 1962 (Switzerland)/03 Julyl 969 (Belgium) PSUR Ol August 2009 - 31 July 2012 Assessor Contact point PSUR assessment checklist Action needed / required Yes No 1. The MAH'S perspective: action proposed? ^ • 2. Does the CCDS contain more information than the SPC? ^ • 3. Outstanding issues previous PSUR assessment? • 4. The MEB's perspective: additional action required? • Quality of provided documentation: 5. Does this PSUR meet Volume 9A requirements? ^ O 6. Does section 4.8 of the SPC meet the current SPC guidelines requirements? CH K Summary of PSUR assessment The MAH submitted a PSUR for Elmex Gel containing Amine Fluoride; Olaflur and dectaflur covenn^h^eno^^^Augui^OO^-^^^ 2012, dated September 2012, by cover letter). Elmex fluoride toothpaste containm^^^^n^Mnm^Iuondes (30.32 mg olaflur and 2.87 mg dectaflur) and 22.1 mg sodium fluoride per gram of gel. This corresponds to a total fluoride content of 1.25 %. Elmex gel is used topically in caries prophylaxis for the fluoridation of tooth enamel. The dental fluid promotes remineralisation of initial caries and is suitable for the treatment of hypersensitive dental necks. In addition, the amine fluorides olaflur/dectaflur have antimicrobial properties. Assessor's comment: A benefit/risk evaluation was lacking with the submission. According to this new pharmacovigilance legislation the MAH should submit a critical benefit-risk evaluation This benefit/risk evaluation should now be submitted with the response.
    [Show full text]